Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study
暂无分享,去创建一个
L. Got | J. Parienti | L. Hocqueloux | T. Prazuck | N. Grégoire | I. Mcnicholl | L. Peyro-Saint-Paul | A. Fournier | S. Brucato | F. Fournel | A. Alix | S. Dargère | J. Bois | Sandrine Lefeuvre | Cécile Valentin
[1] P. Bookstaver,et al. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature. , 2022, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[2] Pia-Allison Roa,et al. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer , 2021, International journal of STD & AIDS.
[3] R. Haubrich,et al. Pilot comparison of the ease of swallowing of single tablet antiretroviral regimens , 2021, AIDS care.
[4] P. Volberding,et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. , 2020, JAMA.
[5] T. M. García,et al. Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties , 2020, The Annals of Pharmacotherapy.
[6] Y. Sawada,et al. Threshold Size of Medical Tablets and Capsules: Based on Information Collected by Japanese Medical Wholesaler , 2020, Patient preference and adherence.
[7] P. Fulco. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer. , 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[8] N. Chueca,et al. Failure to Biktarvy® and development of resistance mutations in an antiretroviral-experienced patient. , 2020, Antiviral research.
[9] Y. Yazdanpanah,et al. Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube. , 2019, Medecine et maladies infectieuses.
[10] E. Gardner,et al. Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France , 2019, Open forum infectious diseases.
[11] Kevin B. McKenney,et al. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single‐Tablet Regimen , 2018, Clinical pharmacology in drug development.
[12] D. Burger,et al. Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure , 2018, The Journal of antimicrobial chemotherapy.
[13] R. van Crevel,et al. Brief Report: Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With or Without Enteral Nutrition , 2017, Journal of acquired immune deficiency syndromes.
[14] V. Shukla,et al. Alternative antiretroviral therapy formulations for patients unable to swallow solid oral dosage forms. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[15] J. Nachega,et al. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.